CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award President and CEO acquired 89,520 shares (grant or award)
- 4 Planned sale Director sold 1,666 shares at $23.39 ($38,968)
- 4 Planned sale Director sold 1,666 shares at $19.13 ($31,871)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Director sold 1,666 shares at $20.66 ($34,420)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 1,666 shares at an average $23.62 ($39,348)
- 144 Insider Sale of Securities
- 4 Open-market sale COFO and Secretary sold 2,522 shares at $23.17 ($58,435)
- 4 Open-market sale Chief Medical Officer sold 2,522 shares at $23.22 ($58,561)
- 4 Open-market sale Chief Medical Officer sold 2,478 shares at $22.60 ($56,003)
- 4 Open-market sale COFO and Secretary sold 2,478 shares at $22.59 ($55,978)
- 4 Open-market sale President and CEO sold 2,309 shares at $22.59 ($52,160)
- 4 Open-market sale Director sold 1,419 shares at $22.60 ($32,069)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Material agreement
Page 13 of 40 · 789 filings